Effect of atorvastatin treatment on the hemorheological and hemostaseological parameters in chronic cerebrovascular patients;Az atorvastatinkezelés haemorrheologiai és haemostaseologiai hatásai krónikus agyérbetegekben

Orvosi Hetilap

Volumn 149, Issue 24, 2008, Pages 1117-1123

  Szapáry, László ^a,b   Horváth, Beáta ^a   Márton, Zsolt ^a   Fehér, Gergely ^a   Tóth, Kálmán ^a   Komoly, Sámuel ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

^b I Belgyógyászati Klinika ^*  (Hungary)

Author keywords

Atorvastatin; Endothelial dysfunction; Hemorheology; Platelet aggregation; von Willebrand factor

Indexed keywords

ANTITHROMBOCYTIC AGENT; ATORVASTATIN; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; BLOOD VISCOSITY; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ERYTHROCYTE AGGREGATION; ERYTHROCYTE DEFORMABILITY; FIBRINOGEN BLOOD LEVEL; HEMATOCRIT; HUMAN; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; LOW DRUG DOSE; THROMBOCYTE AGGREGATION INHIBITION; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ANTICHOLESTEREMIC AGENTS; BLOOD VISCOSITY; CEREBROVASCULAR DISORDERS; CHRONIC DISEASE; DRUG ADMINISTRATION SCHEDULE; ENDOTHELIUM, VASCULAR; ERYTHROCYTE AGGREGATION; ERYTHROCYTE DEFORMABILITY; FEMALE; FIBRINOGEN; HEMATOCRIT; HEMORHEOLOGY; HEMOSTASIS; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PYRROLES; STROKE; VON WILLEBRAND FACTOR;

EID: 47249100232     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2008.28267     Document Type: Article

References (48)

1. Józan P.: Az agyérbetegségek halandóságának néhány fontosabb jellemzoje. Agyérbetegségek, 1998, IV, 2-6.
2. Bonita, R.: Epidemiology of stroke. Lancet, 1992, 339, 342-344.
3. Leonhardt, H., Arntz, H. R., Klemens, U. H.: Studies of plasma viscosity in primary hyperlipoproteinaemia. Atherosclerosis, 1977, 28, 29-40.
4. Callahan, A.: Cerebrovascular disease and statins: a potential addition to the therapeutic armamentarium for stroke prevention. Am. J. Cardiol., 2001, 88, 33J-37J.
5. Prospective Studies Collaboration: Cholesterol, diastolic blood pressure, and stroke: 13 000 strokes in 450 000 people in 45 prospective cohorts. Lancet, 1995, 346, 1647-1653.
6. Hebert, P. R., Gaziano, J. M., Chan, K. S. és mtsai: Cholesterol lowering with statin drugs, risk of stroke, and total mortality. JAMA, 1997, 278, 313-321.
7. Amarenco, P, Labreuche, J., Lavallée, P és mtsai: Statin in stroke prevention and carotid atherosclerosis. Systematic review and up-to-date meta-analysis. Stroke, 2004, 35, 2902-2909.
8. Amarenco, P.: Hypercholesterolemia, lipid lowering agent and the risk of brain infarction. Neurology, 2001, 57, S35-S44.
9. Fisher, M., Herbert, J., Meiselman, J.: Hemorheological factors in cerebral ischemia. Stroke, 1991, 22, 1164-1169.
10. Koenig, W., Ernst, E.: The possible role of hemorheology in atherothrombogenesis. Atherosclerosis, 1992, 94, 9-107.
11. Fisher, M., Herbert, J., Meiselman, J.: Hemorheological factors in cerebral ischemia. Stroke, 1991, 22, 1164-1169.
12. Ernst, E., Resch, K. L., Matrai, A. és mtsai: Impaired blood rheology: risk factor after stroke? J. Intern. Med., 1991, 229, 457-462.
13. Ernst, E: Fibrinogen: Its emerging role as a cardiovascular risk factor. Angiology, 1994, 45, 87-93.
14. Otto, C., Ritter, M. M., Richter, W. O. és mtsai: Hemorheologic abnormalities in defined primary dyslipoproteinemias with both high and low atherosclerotic risks. Metabolism, 2001, 50, 989-990.
15. Seplowitz, A. H., Chien, S., Smith, F. R.: Effects of lipoproteins on plasma viscosity. Atherosclerosis, 1981, 38, 89-95.
16. Rosenson, R. S, Lowe, G. D. O.: Effects of lipids and lipoproteins on thrombosis and rheology. Atherosclerosis, 1988, 140, 271-280.
17. Fuster, V., Badimon, L., Badimon, J. J. és mtsai: The pathogenesis of coronary artery disease and the acute coronary syndromes. New Engl. J. Med., 1992, 326, 242-250.
18. Boda Z.: A haemostasis tényezoi. In: Klinikai hemosztazeológia. Szerk.: Boda Z., Rák IC, Udvardy M. Springer Tudományos Kiadó Kft., Budapest, 2000, 22-40.
19. Bérczi V.: Atherosclerosis és szervi manifestatioi. In: Kardiológia 2000. Szerk.: Temesváry A., Gyenes G. Melania Kft., Budapest, 2000, 85-106.
20. Blann, A. D., McCollum, C. N.: von Willebrand factor, endothelial cell damage and atherosclerosis. Eur. J. Vasc. Surg., 1994, 8, 10-15.
21. Zeiher, A. M, Drexler, H., Saurbier, B. és mtsai: Endothelium-mediated coronary flow modulation in humans: effects of age, atherosclerosis, hypercholesterolemia, and hypertension. J. Clin. Invest., 1993, 92, 652-662.
22. Wassmann, S., Laufs, U., Baumer, A. T. és mtsai: HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension, 2001, 37, 1450-1457.
23. Shiomi, M., Ito, T., Tsukada, T. és mtsai: Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques: effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits. Arterioscler. Thromb. Vasc. Biol., 1995, 15, 1938-1944.
24. Szapary L., Horvath B., Marton Zs. és mtsai: Short term effect of low dose atorvastatin on hemorheological parameters, platelet aggregation and endothelial dysfunction in cerebrovascular patients with hyperlipidemia. CNS Drugs, 2004, 18, 165-172.
25. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evalution, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA, 2001, 285, 2486-2497.
26. Friedewald, W. T., Levy, R. L, Fredrickson, D. S.: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem., 1972, 18, 499-502.
27. Clauss, A.: Gerinnungsphysiologische Schnellmethode zur Bcstimmung des Fibrinogens. Acta Haematol., 1957, 17, 237-246.
28. Klose, H. J., Volger, E., Brechtelsbauer, H. és mtsai: Microrheology and light transmission of blood. Pflugers Arch., 1972, 333, 126-139.
29. Goodall, A. H., Jarvis, J. Chand S. és mtsai: An immunoradiometric assay for human factor VIII/von Willebrand factor (VIII: vWf) using monoclonal antibody that defines a functional epitope. Br. J. Hematol., 1985, 59, 565-577.
30. Elkind, M. S., Flint, A. C., Sciacca, R. R. és mtsai: Lipid-lowering agent use at ischemic stroke onset is associated with decreased mortality. Neurology, 2005, 65, 253-258.
31. Parra, A., Kreiter, K. T., Williams, S. és mtsai: Effect of prior statin use on functional outcome and delayed vasospasm after acute aneurysmal subarachnoid hemorrhage: a matched controlled cohort study. Neurosurgery, 2005, 56, 476-484.
32. Vaugban, C. J., Delanty, N.: Neuroprotective properties of statins in ccrebral ischemia and stroke. Stroke, 1999, 30, 1969-1973.
33. Rubins, H. B., Robins, S. J., Collins, D. és mtsai: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N. Engl. J. Med., 1999, 341, 410-418.
34. The BIP Study Group: Secondary prevention by raising HDL-cholesterol and reducing triglycerides in patienst with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) Study. Circulation, 2000, 102, 21-27.
35. Davidson, M., McKenny, J., Stein, E. és mtsai for the Atorvastatin Study Group I: Comparison of one year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolaemia. Am. J. Cardiol., 1997, 79, 1475-1481.
36. Nawrocki, J. W., Weiss, S. R., Davidson, M. H. és mtsai: Reduction of LDL-cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler. Thromb. Vasc. Biol., 1995, 15, 678-682.
37. The SPARCL Investigators: The Stroke Prevention by Agressive Reduction in Cholesterol Levels (SPARCL) study. Cerebrovasc Dis., 2006, 21 (Suppl. 4), 1. Abstract 1.
38. LaRosa, J. C., Grundy, S. M., Waters, D. D. és mtsai: Treating to New Target (TNT) Investigators. Intensive lipid lowering with atorvastatin in the patients with stable coronary disease. N. Engl. J. Med., 2005, 352, 1425-1435.
39. Law, M. R., Wald, N. J., Rudnicka, A. R.: Quantifying effect of statins on low density lipoprotein cholesterol, ischemic heart disease, and stroke, systematic review and meta-analysis. BMJ, 2003, 326, 1423-1427.
40. Otto, C., Ritter, M. M., Richter, W. O. és mtsai: Hemorheologic abnormalities in defined primary dyslipoproteinemias with both high and low atherosclerotic risks. Metabolism, 2001, 50, 989-990.
41. Vaya, A., Martinez, M., Dalmau, J. és mtsai: Hemorheological changes in children with polygenic hypercholesterolemia. Clin. Hemorheol. Microcirc., 1998, 19, 250-262.
42. Czopf L., Halmosi R., Kesmarky G. és mtsai: Lovastatin and nitrate therapy induced changes in hemorheological parameters and in free radical mediated processes in patients with ischemic heart disease. Perfusion, 1999, 12, 50-58.
43. Wierzbicki, A. S., Lumb, R J., Semra, Y. K. és mtsai: Effect of atorvastatin on plasma fibrinogen. Lancet, 1998, 351, 569-570.
44. Dujove, C. A., Harris, W. S., Altman, R. és mtsai: Effect of atorvastatin on hemorheologic-hemostatic parameters and serum fibrinogen levels in hyperlipidemic patients. Am. J. Cardiol., 2000, 85, 350-353.
45. Tsuda, Y., Satob, K., Kitadai, M. és mtsai: Effects of pravastatin sodium and simvastatin on plasma fibrinogen and blood rheology in type II hypcrcholesterolaemia. Atherosclerosis, 1996, 22, 225-233.
46. Banyai S., Banyai M., Falger J. és mtsai: Atorvastatin improves blood rheology in patients with familial hypercholesterolemia (FH) on long-term apheresis treatment. Atherosclerosis, 2001, 159, 513-519.
47. Galatius, S., Wroblewski, H., Sorensen, V. B. és mtsai: Endothelin and von Willebrand factor as parameters of endothelial function in idiopathic dilated cardiomyopathy: Different stimuli for release before and after heart transplantation? Am. Heart J., 1999, 137, 549-554.
48. Smilde, T. J., Trip, M. D., Wollersbeim, H. és mtsai: Rationale design and baseline characteristics of a clinical trial comparing the effects of robust vs convential cholesterol lowering and intima media thickness in patients with familial hypercholesterolemia: the Atorvastatin versus Simvastatin on Atherosclerosis Progression (ASAP) study. Clin. Drug Invest., 2000, 20, 67-79.